Table 2.
Sample | Total identified peptides | −10IgP [LXRβ] | Coverage LXRβ |
Supporting peptides [LXRβ] | Unique | Amino acids position |
|
---|---|---|---|---|---|---|---|
Peptides | Start | End | |||||
Tumor 2 Rep 1 |
3500 | 46.60 | 7% | L.MIQQLVAAQ.L | No | 226 | 234 |
Q.Q(+.98)LVAAQLQC(+57.02)NK.R | No | 229 | 239 | ||||
Q.VEFINPIFEFSR.A | No | 346 | 357 | ||||
K.RPQDQ(+.98)LR.F | No | 410 | 416 | ||||
Tumor 2 rep 2 | 3971 | 39.62 | 10% | R.RSVVRGGAR.R | No | 113 | 121 |
K.EAGM(+15.99)REQ(+.98)C(+57.02)VLSEEQIRKK.K | No | 151 | 168 | ||||
K.VTPWPLGADPQSR.D | Yes [β1] | 248 | 260 | ||||
K.RPQDQ(+.98)LR.F | No | 410 | 416 | ||||
Tumor 5 Rep 1 |
3713 | 56.33 | 14% | R.SVVRGGAR.R | No | 113 | 121 |
E.LM(+15.99)IQQ(+.98)LVAAQ.L | No | 225 | 234 | ||||
V.QLTAAQ(+.98)ELMIQ(+.98).Q | No | 218 | 228 | ||||
Q.Q(+.98)LVAAQLQC(+57.02)NK.R | No | 229 | 239 | ||||
K.RSFSDQ(+.98)PK.V | No | 240 | 247 | ||||
K.VTPWPLGADPQ(+.98)SR.D | Yes [β1] | 248 | 260 | ||||
A.LQQ(+.98)PYVEALLS.Y | No | 394 | 404 | ||||
E.ALLSYTR.I | No | 401 | 407 | ||||
Tumor 5 Rep 2 |
3412 | 59.82 | 20% | R.RSVVRGGAR.R | No | 113 | 121 |
C.VLSEEQIR.K | No | 159 | 166 | ||||
R.KQ(+.98)QQ(+.98)ESQSQSQSPVGPQG.S | No | 172 | 189 | ||||
E.GVQLTAAQ(+.98)ELMIQ.Q | No | 216 | 228 | ||||
E.LM(+15.99)IQQ(+.98)LVAAQ.L | No | 225 | 234 | ||||
Q.QLVAAQ(+.98)LQ(+.98)C(+57.02)N(+.98)K.R | No | 229 | 239 | ||||
K.RSFSDQ(+.98)PK.V | No | 240 | 247 | ||||
R.EDQIALLK.A | No | 297 | 304 | ||||
A.LQQ(+.98)PYVEALLS.Y | No | 394 | 404 | ||||
K.RPQDQ(+.98)LR.F | No | 410 | 416 |
Amino acids position numbers based on LXRβ1 structure. The gray highlight indicated unique peptides of LXR variant detected by MS.